Abstract:Nanosafety assessment has experienced an intense era of research during the past decades driven by a vivid interest of regulators, industry, and society. Toxicological assays based on in vitro cellular models have undergone an evolution from experimentation using nanoparticulate systems on singular epithelial cell models to employing advanced complex models more realistically mimicking the respective body barriers for analyzing their capacity to alter the immune state of exposed individuals. During this phase, a number of lessons were learned. We have thus arrived at a state where the next chapters have to be opened, pursuing the following objectives: (1) to elucidate underlying mechanisms, (2) to address effects on vulnerable groups, (3) to test material mixtures, and (4) to use realistic doses on (5) sophisticated models. Moreover, data reproducibility has become a significant demand. In this context, we studied the emerging concept of adverse outcome pathways (AOPs) from the perspective of immune activation and modulation resulting in pro-inflammatory versus tolerogenic responses. When considering the interaction of nanomaterials with biological systems, protein corona formation represents the relevant molecular initiating event (e.g., by potential alterations of nanomaterial-adsorbed proteins). Using this as an example, we illustrate how integrated experimental-computational workflows combining in vitro assays with in silico models aid in data enrichment and upon comprehensive ontology-annotated (meta)data upload to online repositories assure FAIRness (Findability, Accessibility, Interoperability, Reusability). Such digital twinning may, in future, assist in early-stage decision-making during therapeutic development, and hence, promote safe-by-design innovation in nanomedicine. Moreover, it may, in combination with in silico-based exposure-relevant dose-finding, serve for risk monitoring in particularly loaded areas, for example, workplaces, taking into account pre-existing health conditions. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials.

The Immunotoxicity Testing and Evaluation of the Medical Devices

[Evaluation of Immunological Toxicity of Medical Devices].

Accelerating medical device biocompatibility evaluation: An industry perspective

A Genomic and Bioinformatics Approach

[Research Status of Nanomaterial Medical Device and Discussion on Biological Evaluation]

Genetically modified immunomodulatory cell-based biomaterials in tissue regeneration and engineering

Research Progress in Mechanisms of Biocompatibility

Recent advances in immunotoxicity and its impact on human health: causative agents, effects and existing treatments

The Current Problems of Regulation of Medical Devices and Countermeasures

The current situation and development of medical device testing institutes in China

A modified HET–CAM approach for biocompatibility testing of medical devices

Cytotoxicity test of medical device with silver nanoparticles

Study on Immunotoxicity of Pesticides

Humanized Mouse Model for Evaluating Biocompatibility and Human Immune Cell Interactions to Biomaterials

Biocompatibility and haemostatic effect investigation of a newly developed biodegradable biopaper with haemostatic and anti-adhesive activity

Next‐Generation Approaches for Biomedical Materials Evaluation: Microfluidics and Organ‐on‐a‐Chip Technologies

[Advances on the Immunotoxicity of Airborne Fine Particulate Matter (PM2.5)].

Biocompatibility of nanomaterials and their immunological properties

Recent applications of immunomodulatory biomaterials for disease immunotherapy

Pathophysiology of the Toxic Effects in Metallic Implants

Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations